Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

The Cost Differential Between Warfarin Versus Aspirin Treatment After a Fontan Procedure.

Schilling C, Dalziel K, Iyengar AJ, d'Udekem Y.

Heart Lung Circ. 2017 Aug;26(8):e44-e47. doi: 10.1016/j.hlc.2017.02.003. Epub 2017 Mar 6.

PMID:
28372885
2.

No difference between aspirin and warfarin after extracardiac Fontan in a propensity score analysis of 475 patients.

Iyengar AJ, Winlaw DS, Galati JC, Wheaton GR, Gentles TL, Grigg LE, Justo RN, Radford DJ, Attard C, Weintraub RG, Bullock A, Sholler GS, Celermajer DS, d'Udekem Y; Australia and New Zealand Fontan Registry.

Eur J Cardiothorac Surg. 2016 Nov;50(5):980-987. Epub 2016 May 26.

PMID:
27229665
3.

The economic costs of routine INR monitoring in infants and children--examining point-of-care devices used within the home setting compared to traditional anticoagulation clinic monitoring.

Gaw JR, Crowley S, Monagle P, Jones S, Newall F.

Thromb Res. 2013 Jul;132(1):26-31. doi: 10.1016/j.thromres.2013.04.028. Epub 2013 Jun 6.

PMID:
23746471
4.

Effect of aspirin and warfarin therapy on thromboembolic events in patients with univentricular hearts and Fontan palliation.

Potter BJ, Leong-Sit P, Fernandes SM, Feifer A, Mayer JE Jr, Triedman JK, Walsh EP, Landzberg MJ, Khairy P.

Int J Cardiol. 2013 Oct 9;168(4):3940-3. doi: 10.1016/j.ijcard.2013.06.058. Epub 2013 Jul 17.

PMID:
23870650
5.

Cost effectiveness of warfarin versus aspirin in patients older than 75 years with atrial fibrillation.

Jowett S, Bryan S, Mant J, Fletcher K, Roalfe A, Fitzmaurice D, Lip GY, Hobbs FD.

Stroke. 2011 Jun;42(6):1717-21. doi: 10.1161/STROKEAHA.110.600767. Epub 2011 Apr 21.

PMID:
21512184
6.

Economic Evaluation of the Combined Use of Warfarin and Low-dose Aspirin Versus Warfarin Alone in Mechanical Valve Prostheses.

El-Hamamsy MH, Elsisi GH, Eldessouki R, Elmazar MM, Taha AS, Awad BF, Elmansy H.

Appl Health Econ Health Policy. 2016 Aug;14(4):431-440. doi: 10.1007/s40258-016-0238-1.

PMID:
27028445
7.

Hospital Inpatient Costs for Single Ventricle Patients Surviving the Fontan Procedure.

Huang L, Schilling C, Dalziel KM, Xie S, Celermajer DS, McNeil JJ, Winlaw D, Hornung TS, Radford DJ, Grigg LE, Bullock A, Wheaton GR, Justo RN, Blake J, Bishop R, Du Plessis K, d'Udekem Y.

Am J Cardiol. 2017 Aug 1;120(3):467-472. doi: 10.1016/j.amjcard.2017.04.049. Epub 2017 May 11.

PMID:
28583678
8.

A multicenter, randomized trial comparing heparin/warfarin and acetylsalicylic acid as primary thromboprophylaxis for 2 years after the Fontan procedure in children.

Monagle P, Cochrane A, Roberts R, Manlhiot C, Weintraub R, Szechtman B, Hughes M, Andrew M, McCrindle BW; Fontan Anticoagulation Study Group.

J Am Coll Cardiol. 2011 Aug 2;58(6):645-51. doi: 10.1016/j.jacc.2011.01.061.

9.

Safety of warfarin dosing in the intensive care unit following the Fontan procedure.

Thomas CA, Taylor K, Schamberger MS, Rotta AT.

Congenit Heart Dis. 2014 Jul-Aug;9(4):361-5.

PMID:
25247218
11.
12.

Cost-effectiveness of apixaban versus warfarin and aspirin in Sweden for stroke prevention in patients with atrial fibrillation.

Lanitis T, Kongnakorn T, Jacobson L, De Geer A.

Thromb Res. 2014 Aug;134(2):278-87. doi: 10.1016/j.thromres.2014.05.027. Epub 2014 May 26.

13.

The Long-Term Management of Children and Adults with a Fontan Circulation: A Systematic Review and Survey of Current Practice in Australia and New Zealand.

Gnanappa GK, Celermajer DS, Sholler GF, Gentles T, Winlaw D, d'Udekem Y, Ayer J.

Pediatr Cardiol. 2017 Jan;38(1):56-69. doi: 10.1007/s00246-016-1484-6. Epub 2016 Oct 27. Review.

PMID:
27787594
14.

Hospital costs and cost implications of co-morbid conditions for patients with single ventricle in the period through to Fontan completion.

Huang L, Dalziel KM, Schilling C, Celermajer DS, McNeil JJ, Winlaw D, Gentles T, Radford DJ, Cheung M, Bullock A, Wheaton GR, Justo RN, Selbie LA, Forsdick V, Du Plessis K, d'Udekem Y.

Int J Cardiol. 2017 Aug 1;240:178-182. doi: 10.1016/j.ijcard.2017.04.056. Epub 2017 Apr 20.

PMID:
28456482
15.

Anticoagulation control and cost of monitoring of older patients on chronic warfarin therapy in three settings in North East England.

Abohelaika S, Kamali F, Avery P, Robinson B, Kesteven P, Wynne H.

Age Ageing. 2014 Sep;43(5):708-11. doi: 10.1093/ageing/afu074. Epub 2014 Jun 18.

PMID:
24947831
16.

Cost Effectiveness of Apixaban versus Warfarin or Aspirin for Stroke Prevention in Patients with Atrial Fibrillation: A Greek Perspective.

Athanasakis K, Boubouchairopoulou N, Karampli E, Tarantilis F, Savvari P, Bilitou A, Kyriopoulos J.

Am J Cardiovasc Drugs. 2017 Apr;17(2):123-133. doi: 10.1007/s40256-016-0204-1.

PMID:
27882517
17.

Comparison of Medical Costs of Patients With Atrial Fibrillation Unsuitable for Warfarin Treatment With Apixaban or Aspirin Based on AVERROES Trial.

Amin A, Deitelzweig S, Jing Y, Makenbaeva D, Wiederkehr D, Lin J, Graham J.

Clin Appl Thromb Hemost. 2015 Apr;21(3):235-40. doi: 10.1177/1076029613507335. Epub 2013 Oct 9.

PMID:
24108232
18.

Out-of-range international normalized ratio values and healthcare cost among new warfarin patients with non-valvular atrial fibrillation.

Nelson WW, Wang L, Baser O, Damaraju CV, Schein JR.

J Med Econ. 2015 May;18(5):333-40. doi: 10.3111/13696998.2014.1001851. Epub 2015 Feb 6.

PMID:
25549062
20.

The Fontan epidemic: Population projections from the Australia and New Zealand Fontan Registry.

Schilling C, Dalziel K, Nunn R, Du Plessis K, Shi WY, Celermajer D, Winlaw D, Weintraub RG, Grigg LE, Radford DJ, Bullock A, Gentles TL, Wheaton GR, Hornung T, Justo RN, d'Udekem Y.

Int J Cardiol. 2016 Sep 15;219:14-9. doi: 10.1016/j.ijcard.2016.05.035. Epub 2016 May 14.

PMID:
27257850

Supplemental Content

Support Center